23 October 2020
The US Food and Drug Administration has approved Gilead Sciences‘ antiviral drug Veklury (remdesivir) to treat hospitalised Covid-19 patients. Veklury stops the replication of the SARS-CoV-2 virus that caused Covid-19. It is the first and the only approved drug for Covid-19 in the US and is abundantly available due to early investment efforts by the country to maximise its supply.
Go deeper with GlobalData
Roche and Atea Pharmaceuticals have collaborated to develop the AT-527, an oral direct-acting antiviral (DAA) for Covid-19. AT-527 blocks the viral RNA polymerase enzyme and is currently in Phase II trials for hospitalised Covid-19 patients suffering with moderate symptoms. The antiviral drug will also undergo a phase 3 trial to understand its use in patients outside hospitals and in post-exposure preventive scenario.
The International AIDS Vaccine Initiative and the Serum Institute of India have entered into an agreement with Merck to develop SARS-CoV-2 neutralising monoclonal antibodies (mAbs) to fight the Covid-19 disease. The mAbs have been co-invented by IAVI and Scripps Research; this partnership is unique because it ensures equitable global access to innovative therapies for Covid-19.
The San Antonio Medical Foundation has awarded a grant to Doug E. Frantz, a researcher from the University of Texas at San Antonio to support his work on a novel Covid-19 drug. Frantz will be assisted in his research by the UT Health San Antonio and Southwest Research Institute.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
